Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-05T05:11:09.821Z Has data issue: false hasContentIssue false
  • English
  • Français

Progress in Neurotherapeutics and Neuropsychopharmacology 2008

Published online by Cambridge University Press:  16 January 2008

Jeffrey L. Cummings
Jeffrey L. Cummings
Affiliation:
Departments of Neurology and Psychiatry and Behavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Extract

ABSTRACT

There has been continuous progress in neurotherapeutics and neuropsychopharmacology in the past year. Notable are the reports of successful preliminary disease-modifying trials in Niemann-Pick disease and Friedreich's ataxia. Progress also has been made in treatment of migraine, stroke, epilepsy, multiple sclerosis, traumatic brain injury, and pain. Biomarkers are increasingly used to establish proof of pharmacology including measures of cerebrospinal fluid constituents and brain changes on magnetic resonance imaging. There is an increasing diversity of patient populations participating in clinical trials, including pediatric migraine and traumatic brain injury.

Keywords

argatrobanatorvastatinbiomarkersbipolar depressionclinical trialsdeep brain stimulationdepressiondisease modificationduloxatineepilepsyfingolimodFriedreich's ataxiaglatiramer acetateHuntington's diseaseIdebenonemethylphenidatemiglustatmigrainemodafinilmultiple sclerosisneuropathic painnicardipineNiemann-Pick Type C diseaseParkinson's diseasepharmacogeneticspregabalinretigabinriluzoleritogitinerivastigminerizatripanschizophreniaspinal cord injury paintestosteronetramiprosatetranscranial magnetic stimulationtraumatic brain injuryzolmitriptanzonisamide.
Type
Research Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 3 , Issue 1 , January 2008 , pp. 1 - 11
Copyright
© 2008 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ahonen, K., Hämäläinen, M., Eerola, M., & Hoppu, K. (2006). A randomized trial of rizatriptan in migraine attacks in children. Neurology, 67, 1135–1140.Google Scholar
Aisen, P.S., Saumier, D., Briand, R., et al. (2006). A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology, 67, 1757–1763.Google Scholar
Amsterdam, J.D., & Bodkin, J.A. (2006). Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. Journal of Clinical Psychopharmacology, 26, 579–586.Google Scholar
Barth, M., Capelle, H.H., Weidauer, S., Weiss, C., Mönch, E., Thomé, C., Luecke, T., Schmiedek, P., Kasuya, H., & Vajkoczy, P. (2007). Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke, 38, 330–336.Google Scholar
Cittadini, E., May, A., Straube, A., Evers, S., Bussone, G., & Goadsby, P.J. (2006). Effectiveness of Intranasal Zolmitriptan in acute cluster headache. Archives of Neurology, 63, 1537–1542.Google Scholar
Cohen, J.A., Rovaris, M., Goodman, A.D., Ladkani, D., Wynn, D., & Filippi, M. (9006 Study Group) (2007). Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology, 68, 939–944.Google Scholar
Corya, S., Williamson, D., Sanger, T., Briggs, S., Case, M., & Tollefson, G. (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and Anxiety, 23, 364–372.Google Scholar
Denys, D., Van Nieuwerburgh, F., Deforce, D., & Westenberg, H. (2007). Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive–compulsive disorder in a randomized, double-blind trial. Journal of Clinical Psychiatry, 68, 747–753.Google Scholar
Deuschl, G., Schade-Brittinger, C., Krack, O., et al. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine, 355, 896–908.Google Scholar
Di Prospero, N., Baker, A., Jeffries, N., & Fischbeck, K. (2007). Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurology, 6, 878–886.Google Scholar
ESPRIT Group (2007). Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurology, 6, 115–124.Google Scholar
Fawcett, J., Curt, A., Steeves, J., et al. (2007). Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord, 45, 190–205.Google Scholar
Fregni, F., Boggio, P., Lima, M.C., et al. (2006). A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain, 122, 197–209.Google Scholar
Giladi, N., Boroojerdi, B., Korczyn, A.D., Burn, D.J., Clarke, C.E., & Schapira, A.H. (SP513 Investigators) (2007). Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Movement Disorders, 22, 2398–2404.Google Scholar
Hessen, E., Lossius, M.I., Reinvang, I., & Gjerstad, L. (2007). Influence of major antiepileptic drugs on neuropsychological function: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients on monotherapy. Journal of the International Neuropsychological Society, 13, 393–400.Google Scholar
Jankovic, J., Watts, R., Martin, W., & Boroojerdi, B. (2007). Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Archives of Neurology, 64, 676–682.Google Scholar
Kornstein, S., Bose, A., Li, D., Saikali, K., & Gandhi, C. (2006). Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 67, 1767–1775.Google Scholar
Landwehrmeyer, G., Dubois, B., de Yébenes, J., et al. (2007). Riluzole in Huntington's disease: a 3-year, randomized controlled study. Annals of Neurology, 62, 262–272.Google Scholar
Lindenmayer, J., Khan, A., Iskander, A., Abad, M., & Parker, B. (2007). A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry, 68, 368–379.Google Scholar
Marson, A.G., Al-Kharusi, A.M., Alwaidh, M., et al. (2007). The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, 369, 1016–1026.Google Scholar
Miller, D.H., Soon, D., Fernando, K.T., MacManus, D.G., Barker, G.J., Yousry, T.A., Fisher, E., O'Connor, P.W., Phillips, J.T., Polman, C.H., Kappos, L., Hutchinson, M., Havrdova, E., Lublin, F.D., Giovannoni, G., Wajgt, A., Rudick, R., Lynn, F., Panzara, M.A., & Sandrock, A.W. (AFFIRM Investigators) (2007). MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology, 68, 1390–1401.Google Scholar
Mizuno, Y., Kanazawa, I., Kuno, S., Yanagisawa, N., Yamamoto, M., & Kindo, T. (2007). Placebo-controlled, double-blind close-finding study of entacapone in fluctuating Parkinsonian patient. Movement Disorders, 22, 75–80.Google Scholar
Moein, H., Khalili, H.A., & Keramatian, K. (2006). Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clinical Neurology and Neurosurgery, 108, 539–542.Google Scholar
Murata, M., Hasegawa, K., Kanazawa, I., & Group TJZoPS (2007). Zonisamide improves motor function in Parkinson disease. Neurology, 68, 45–50.Google Scholar
Pahwa, R., Stacy, M., Factor, S., et al. (2007). Ropinirole 24-hour prolonged release. Neurology, 68, 1108–1115.Google Scholar
Patterson, M.C., Vecchio, D., Prady, H., Abel, L., & Wraith, J.E. (2007). Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurology, 6, 765–772.Google Scholar
Pierre, J.M., Peloian, J.H., Wirshing, D.A., Wirshing, W.C., & Marder, S.R. (2007). A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. Journal of Clinical Psychiatry, 68, 705–710.Google Scholar
Poewe, W.H., Rascol, O., Quinn, N., et al. (2007). Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurology, 6, 513–520.Google Scholar
Porter, R.J., Partiot, A., Sachdeo, R., Nohria, V., & Alves, W.M. (2007). Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology, 68, 1197–1204.Google Scholar
Sachs, G., Nierenberg, A., Calabrese, J.R., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 357, 1711–1722.Google Scholar
Schupbach, W.M., Maltete, D., Houeto, J.L., et al. (2007). Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology, 686, 267–271.Google Scholar
Sicotte, N.L., Giesser, B., Tandon, V., et al. (2007). Testosterone treatment in multiple sclerosis. Archives of Neurology, 64, 683–688.Google Scholar
Siddall, P., Cousins, M., Otte, A., Griesing, T., Chambers, R., & Murphy, T. (2006). Pregabalin in central neuropathic pain associated with spinal cord injury. Neurology, 67, 1792–1800.Google Scholar
Silver, J., Koumaras, B., Chen, M., et al. (2006). Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology, 67, 748–758.Google Scholar
SPARCL (2006). High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 355, 549–559.
Steeves, J., Lammertse, D., Curt, A., et al. (2007). Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord, 45, 206–221.Google Scholar
Sugg, R., Pary, J., Uchino, K., et al. (2006). Argatroban tPA stroke study. Archives of Neurology, 63, 1057–1062.Google Scholar
Swartz, M.S., Perkins, D.O., Stroup, T.S., et al. (2007). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry, 164, 428–436.Google Scholar
Warren, K.G., Catz, I., Ferenczi, L.Z., & Krantz, J. (2006). Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. European Journal of Neurology, 13, 887–895.Google Scholar
Watts, R.L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B., & Rao, J. (2007). Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology, 68, 272–276.Google Scholar
Wernicke, J., Pritchett, Y., D'Souza, D., et al. (2006). A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology, 67, 1411–1420.Google Scholar
Wolinsky, J., Narayana, P., O'Connor, P., et al. (2007). Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology, 61, 14–24.Google Scholar